Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.

Michael Roth, M.D.

University of California, Los Angeles # of Grants: 2


Developing new vaccines for lung cancer 1998 (Cycle 7) $398,511
Cancer Research Project Awards

Regulation of Natural Killer Cell Activity by Theophylline 1994 (Cycle 3) $172,231
Pulmonary Disease Research Project Awards

Increased dendritic cell number and function following continuous in vivo infusion of GM-CSF and IL-4.
Periodical: Blood Index Medicus:
Authors: Basak SK, Harui A, Stolina M, Sharma S, et. al. ART
Yr: 2002 Vol: 99 Nbr: 8 Abs: Pg: 2869 - 2879

Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses.
Periodical: Journal of Immunology Index Medicus:
Authors: Roth MD, Cheng Q, Harui A, et. al. ART
Yr: 2002 Vol: 169 Nbr: 8 Abs: Pg:

Inhibition of natural killer cell activity by therapeutic levels of theophylline
Periodical: American Journal of Respiratory Cell and Molecular Biology Index Medicus:
Authors: Coskey LA, Bitting J, Roth MD ART
Yr: 1993 Vol: 9 Nbr: 6 Abs: Pg: 659-665

Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4
Periodical: Journal of Leukocyte Biology Index Medicus:
Authors: Kiertscher SM, Roth MD ART
Yr: 1995 Vol: Nbr: Abs: Pg: